Precision BioSciences Inc (DTIL) shareholders
Close on Nov 17, 2026Market cap $194.59MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Octagon Capital Advisors LP Joint filing with Octagon Investments Master Fund LP (9.99%), Ting Jia (9.99%) | 2,328,485 | 9.99% | 13G (passive) | Dec 31, 2025 |
| abrdn Inc. Joint filing with Aberdeen Group plc (8.88%) | 2,138,603 | 8.88% | 13G (passive) | Dec 31, 2025 |
| Empery Asset Management, LP Joint filing with Ryan M. Lane (7.63%) | 1,968,879 | 7.63% | 13G (passive) amendment | Mar 31, 2026 |
| Bleichroeder LP Joint filing with Bleichroeder Holdings LLC (8.21%), Andrew Gundlach (8.21%) | 1,900,000 | 8.21% | 13G (passive) amendment | Dec 31, 2025 |
| Ting Jia Joint filing with Octagon Capital Advisors LP (5.73%), Octagon Investments Master Fund LP (5.73%) | 1,651,497 | 5.73% | 13G (passive) amendment | Sep 30, 2026 |
| Weston Nichols Joint filing with Lynx1 Capital Management LP (5.40%) | 1,390,611 | 5.40% | 13G (passive) | Jul 13, 2026 |
| BlackRock, Inc. | 1,384,230 | 5.01% | 13G (passive) | Sep 30, 2026 |
| Matthew Smith Joint filing with Readout Capital, LP (9.30%), Readout Capital GP, LLC (9.30%) and 2 more | 1,119,311 | 9.40% | 13G (passive) amendment | Jun 30, 2025 |
| Marc Schneidman Joint filing with Aquilo Capital Management, LLC (9.90%), Aquilo Capital, L.P. (6.60%) | 791,862 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (5.90%), Perceptive Life Sciences Master Fund, Ltd. (5.90%) | 426,293 | 5.90% | 13G (passive) amendment | Sep 30, 2024 |
| Novartis Pharma AG Joint filing with Novartis AG (5.40%) | 413,581 | 5.40% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DTIL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| abrdn plc | 2,230,178 | 8.08% | $17.53M | – | 0.02% |
| Bleichroeder LP | 2,018,190 | 7.31% | $15.86M | +355,690 | 2.84% |
| Octagon Capital Advisors LP | 1,350,000 | 4.89% | $10.61M | −886,732 | 0.95% |
| Boothbay Fund Management, LLC | 1,346,004 | 4.88% | $10.58M | +279,954 | 0.14% |
| BlackRock, Inc. | 1,172,873 | 4.25% | $9.22M | +973,112 | 0.00% |
| Vanguard Capital Management LLC | 1,116,241 | 4.04% | $8.77M | +205,501 | 0.00% |
| Lynx1 Capital Management LP | 950,466 | 3.44% | $7.47M | −34,647 | 0.86% |
| Driehaus Capital Management LLC | 946,707 | 3.43% | $7.44M | −48,664 | 0.04% |
| Empery Asset Management, LP | 776,093 | 2.81% | $6.10M | −1,192,786 | 7.05% |
| Affinity Asset Advisors, LLC | 646,576 | 2.34% | $5.08M | +48,630 | 0.23% |
| Geode Capital Management, LLC | 620,981 | 2.25% | $4.88M | +333,891 | 0.00% |
| Mackenzie Financial Corp | 480,997 | 1.74% | $3.78M | New | 0.00% |
| State Street Corp | 427,325 | 1.55% | $3.36M | +354,383 | 0.00% |
| Acadian Asset Management LLC | 305,759 | 1.11% | $2.40M | +260,991 | 0.00% |
| ArrowMark Colorado Holdings LLC | 274,140 | 0.99% | $2.15M | +95,000 | 0.09% |
| Corient Private Wealth LLC | 245,058 | 0.89% | $1.93M | +101,206 | 0.00% |
| Two Sigma Investments, LP | 237,863 | 0.86% | $1.87M | −69,927 | 0.00% |
| Northern Trust Corp | 190,188 | 0.69% | $1.49M | +114,119 | 0.00% |
| JPMorgan Chase & Co | 180,452 | 0.65% | $1.43M | +180,444 | 0.00% |
| Vanguard Fiduciary Trust Co | 166,538 | 0.60% | $1.31M | +10,912 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 95 | 18M | 64.0% | 31 / 31 | 14 / 13 | 5M | 3M |
| Q1 2026 | 78 | 16M | 58.5% | 21 / 24 | 13 / 11 | 4M | 2M |
| Q4 2025 | 69 | 15M | 54.7% | 21 / 22 | 8 / 8 | 11M | 1M |
| Q3 2025 | 56 | 5M | 16.8% | 11 / 15 | 10 / 7 | 1M | 0M |
| Q2 2025 | 52 | 4M | 16.2% | 11 / 14 | 8 / 7 | 2M | 1M |
| Q1 2025 | 48 | 4M | 13.7% | 6 / 9 | 11 / 12 | 1M | 1M |
| Q4 2024 | 55 | 4M | 14.1% | 14 / 18 | 9 / 10 | 2M | 1M |
| Q3 2024 | 51 | 3M | 12.0% | 8 / 10 | 9 / 3 | 0M | 0M |
| Q2 2024 | 47 | 3M | 11.5% | 8 / 10 | 14 / 4 | 0M | 0M |
| Q1 2024 | 43 | 3M | 11.6% | 43 / 0 | 0 / 0 | 3M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
61 funds held DTIL in Q2 2026, 66% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of DTIL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 778,139 | 2.82% | $6.12M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 427,167 | 1.55% | $3.36M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 312,368 | 1.13% | $2.46M | 0.00% | Jun 30, 2026 |
| Meridian Contrarian Fund | 274,140 | 0.99% | $2.15M | 0.32% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 261,845 | 0.95% | $1.83M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 168,208 | 0.61% | $1.32M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 126,684 | 0.46% | $882.99K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 75,800 | 0.27% | $595.79K | 0.04% | Jun 30, 2026 |
| JPMorgan U.S. Small Company Fund | 61,076 | 0.22% | $480.06K | 0.04% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 58,327 | 0.21% | $407.71K | 0.01% | Jul 31, 2026 |
| Jacob Discovery Fund | 52,089 | 0.19% | $363.06K | 2.26% | May 31, 2026 |
| Fidelity Total Market Index Fund | 48,562 | 0.18% | $338.48K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 37,496 | 0.14% | $261.35K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 34,175 | 0.12% | $268.62K | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Value Index Fund | 33,566 | 0.12% | $263.83K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Amoroso | President and CEO, Director | 243,392 | 0.88% | Jun 3, 2026 |
| Dario Scimeca | Chief Legal Officer | 56,782 | 0.21% | Nov 12, 2026 |
| Naresh Haresh Tanna | Chief Financial Officer | 25,575 | 0.09% | Aug 3, 2026 |
| Cassandra Louise Gorsuch | Chief Scientific Officer | 16,028 | 0.06% | Aug 3, 2026 |
| Mei Zhang Lu Burris | Chielf Accounting Officer | 5,115 | 0.02% | Aug 3, 2026 |
| John Alexander Kelly | Chief Financial Officer | 125,883 | 0.46% | Jun 3, 2026 |
| J. Jefferson Smith | Chief Research Officer | 129,857 | 0.47% | Jun 3, 2026 |
| Stanley Frankel | Director | 41,478 | 0.15% | Sep 30, 2026 |
| Geno J. Germano | Director | 47,492 | 0.17% | Sep 29, 2026 |
| Melinda Brown | Director | 45,481 | 0.16% | Sep 29, 2026 |
| Kevin Buehler | Director | 49,137 | 0.18% | Jun 5, 2026 |
| Shari Lisa Pire | Director | 35,028 | 0.13% | Jun 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dario Scimeca Chief Legal Officer | Nov 10, 2026 | Sale(10b5-1 plan) | −2,821 | $9.75 | $27.50K | 56,782 |
| Stanley Frankel Director | Sep 28, 2026 | Buy | +1,000 | $6.00 | $6.00K | 41,478 |
| Geno J. Germano Director | Sep 25, 2026 | Buy | +2,609 | $6.28 | $16.38K | 47,492 |
| Melinda Brown Director | Sep 25, 2026 | Buy | +1,135 | $6.27 | $7.12K | 45,481 |
| Geno J. Germano Director | May 20, 2026 | Option exercise | +21,000 | – | – | 44,883 |
| Kevin Buehler Director | May 20, 2026 | Option exercise | +21,000 | – | – | 49,137 |
| Stanley Frankel Director | May 20, 2026 | Option exercise | +21,000 | – | – | 40,478 |
| Melinda Brown Director | May 20, 2026 | Option exercise | +21,000 | – | – | 44,346 |
| Shari Lisa Pire Director | May 20, 2026 | Option exercise | +21,000 | – | – | 35,028 |
| Dario Scimeca General Counsel and Secretary | Feb 18, 2026 | Sale(10b5-1 plan) | −4,925 | $3.84 | $18.91K | 56,457 |
| J. Jefferson Smith Chief Research Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −4,925 | $3.84 | $18.91K | 121,926 |
| John Alexander Kelly Chief Financial Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −8,149 | $3.84 | $31.29K | 125,883 |
| Michael Amoroso President and CEO, Director | Feb 18, 2026 | Sale(10b5-1 plan) | −20,559 | $3.84 | $78.95K | 243,392 |
| Dario Scimeca General Counsel and Secretary | Feb 17, 2026 | Option exercise | +16,667 | – | – | 61,382 |
| J. Jefferson Smith Chief Research Officer | Feb 17, 2026 | Option exercise | +16,667 | – | – | 126,851 |
| John Alexander Kelly Chief Financial Officer | Feb 17, 2026 | Option exercise | +27,584 | – | – | 134,032 |
| Michael Amoroso President and CEO, Director | Feb 17, 2026 | Option exercise | +67,797 | – | – | 263,951 |
| Michael Amoroso President and CEO, Director | Jan 22, 2026 | Sale(10b5-1 plan) | −34,799 | $4.17 | $145.11K | 196,154 |
| John Alexander Kelly Chief Financial Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −15,213 | $4.03 | $61.31K | 106,448 |
| Dario Scimeca General Counsel and Secretary | Jan 21, 2026 | Sale(10b5-1 plan) | −8,854 | $4.03 | $35.68K | 44,715 |
| J. Jefferson Smith Chief Research Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −10,200 | $4.03 | $41.11K | 110,184 |
| J. Jefferson Smith Chief Research Officer | Jan 21, 2026 | Option exercise | +16,219 | – | – | 120,384 |
| John Alexander Kelly Chief Financial Officer | Jan 20, 2026 | Option exercise | +3,888 | – | – | 81,186 |
| John Alexander Kelly Chief Financial Officer | Jan 20, 2026 | Option exercise | +26,575 | – | – | 121,661 |
| John Alexander Kelly Chief Financial Officer | Jan 20, 2026 | Option exercise | +13,900 | – | – | 95,086 |
| Michael Amoroso President and CEO, Director | Jan 20, 2026 | Option exercise | +69,421 | – | – | 230,953 |
| Michael Amoroso President and CEO, Director | Jan 20, 2026 | Option exercise | +8,888 | – | – | 124,463 |
| Michael Amoroso President and CEO, Director | Jan 20, 2026 | Option exercise | +37,069 | – | – | 161,532 |
| Dario Scimeca General Counsel and Secretary | Jan 20, 2026 | Option exercise | +14,908 | – | – | 53,569 |
| Dario Scimeca General Counsel and Secretary | Jan 20, 2026 | Option exercise | +8,425 | – | – | 38,661 |
| Dario Scimeca General Counsel and Secretary | Jan 20, 2026 | Option exercise | +1,978 | – | – | 30,236 |
| J. Jefferson Smith Chief Research Officer | Jan 20, 2026 | Option exercise | +2,500 | – | – | 93,718 |
| J. Jefferson Smith Chief Research Officer | Jan 20, 2026 | Option exercise | +10,447 | – | – | 104,165 |
| Geno J. Germano Director | Dec 16, 2025 | Buy | +3,000 | $4.72 | $14.16K | 23,883 |
| Stanley Frankel Director | Dec 16, 2025 | Buy | +2,700 | $4.70 | $12.69K | 19,478 |
| Melinda Brown Director | Dec 15, 2025 | Buy | +1,381 | $4.97 | $6.86K | 23,346 |
| Dario Scimeca General Counsel and Secretary | Nov 3, 2025 | Sale(10b5-1 plan) | −665 | $6.49 | $4.32K | 28,258 |
| Michael Amoroso President and CEO, Director | Nov 3, 2025 | Sale(10b5-1 plan) | −3,409 | $6.49 | $22.12K | 115,575 |
| John Alexander Kelly Chief Financial Officer | Nov 3, 2025 | Sale(10b5-1 plan) | −1,303 | $6.49 | $8.46K | 77,298 |
| Dario Scimeca General Counsel and Secretary | Nov 2, 2025 | Option exercise | +1,835 | – | – | 28,923 |
| Michael Amoroso President and CEO, Director | Nov 2, 2025 | Option exercise | +9,444 | – | – | 118,984 |
| John Alexander Kelly Chief Financial Officer | Nov 2, 2025 | Option exercise | +3,605 | – | – | 78,601 |
| Stanley Frankel Director | Sep 26, 2025 | Buy | +2,700 | $4.97 | $13.42K | 16,778 |
| Melinda Brown Director | Sep 22, 2025 | Buy | +1,400 | $4.89 | $6.85K | 21,965 |
| John Alexander Kelly Chief Financial Officer | Jul 3, 2025 | Sale(10b5-1 plan) | −14,827 | $4.26 | $63.16K | 73,485 |
| Kevin Buehler Director | Jun 25, 2025 | Buy | +5,076 | $4.16 | $21.12K | 28,137 |
| Melinda Brown Director | Jun 25, 2025 | Buy | +1,682 | $4.14 | $6.96K | 20,565 |
| Geno J. Germano Director | May 27, 2025 | Option exercise | +9,826 | – | – | 20,883 |
| Kevin Buehler Director | May 27, 2025 | Option exercise | +9,826 | – | – | 23,061 |
| Melinda Brown Director | May 27, 2025 | Option exercise | +9,826 | – | – | 18,883 |
| Shari Lisa Pire Director | May 27, 2025 | Option exercise | +9,826 | – | – | 14,028 |
| Stanley Frankel Director | May 27, 2025 | Option exercise | +9,826 | – | – | 14,078 |
| Melinda Brown Director | Mar 26, 2025 | Buy | +1,839 | $4.75 | $8.74K | 9,057 |
| Kevin Buehler Director | Mar 26, 2025 | Buy | +4,523 | $4.67 | $21.12K | 13,235 |
| Geno J. Germano Director | Mar 25, 2025 | Buy | +3,250 | $5.30 | $17.23K | 11,057 |
| Michael Amoroso President and CEO, Director | Mar 24, 2025 | Sale(10b5-1 plan) | −964 | $5.56 | $5.36K | 109,540 |
| Michael Amoroso President and CEO, Director | Mar 21, 2025 | Option exercise | +3,417 | – | – | 110,504 |
| J. Jefferson Smith Chief Research Officer | Mar 4, 2025 | Sale(10b5-1 plan) | −154 | $4.91 | $756 | 87,805 |
| Dario Scimeca General Counsel and Secretary | Mar 4, 2025 | Sale(10b5-1 plan) | −272 | $4.91 | $1.34K | 25,000 |
| John Alexander Kelly Chief Financial Officer | Mar 3, 2025 | Option exercise | +1,702 | – | – | 86,256 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Precision BioSciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 32,729 shares on Sep 23, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Dario Scimeca Officer | Nov 10, 2026 | 2,821 | $27.52K | Nov 10, 2026 | ESPP Purchase |
| J. Jefferson Smith Officer | Nov 6, 2026 | 875 | $8.96K | Nov 6, 2026 | Founders Shares |
| J. Jefferson Smith Officer | Nov 5, 2026 | 7,056 | $72.41K | Nov 5, 2026 | Founder Shares |
| J. Jefferson Smith Officer | Feb 18, 2026 | 4,925 | $18.93K | Feb 18, 2026 | Restricted Stock Vesting |
| Michael Amoroso Officer, Director | Feb 18, 2026 | 20,559 | $79.02K | Feb 18, 2026 | Restricted Stock Vesting |
| Dario Scimeca Officer | Feb 18, 2026 | 4,925 | $18.93K | Feb 18, 2026 | Restricted Stock Vesting |
| John Alexander Kelly Officer | Feb 18, 2026 | 8,149 | $31.32K | Feb 18, 2026 | Restricted Stock Vesting |
| Michael Amoroso Officer, Director | Jan 22, 2026 | 34,799 | $145.20K | Jan 22, 2026 | Restricted Stock Vesting |
| Dario Scimeca Officer | Jan 21, 2026 | 8,854 | $35.65K | Jan 21, 2026 | Restricted Stock Vesting |
| J. Jefferson Smith Officer | Jan 21, 2026 | 10,200 | $41.07K | Jan 21, 2026 | Restricted Stock Vesting |
| John Alexander Kelly Officer | Jan 21, 2026 | 15,213 | $61.26K | Jan 21, 2026 | Restricted Stock Vesting |
| John Alexander Kelly Officer | Nov 3, 2025 | 1,303 | $8.46K | Nov 3, 2025 | Restricted Stock Vesting |
| Michael Amoroso Officer, Director | Nov 3, 2025 | 3,409 | $22.12K | Nov 3, 2025 | Restricted Stock Vesting |
| Dario Scimeca Officer | Nov 3, 2025 | 665 | $4.32K | Nov 3, 2025 | Restricted Stock Vesting |
| John Alexander Kelly Officer | Jul 3, 2025 | 14,827 | $63.21K | Jul 3, 2025 | Restricted Stock Vesting |
See a number that looks wrong?